Live from the NIH registry
Studies recruiting near Fargo right now
Top 25 of 198 recruiting studies, sorted by proximity — each links to its official registry page
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
Sanford Health- Fargo — Fargo, North Dakota (2.0 mi)
· Sponsor: American Society of Clinical Oncology
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 2
Interventional 81 participants sought
Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Sanford Broadway Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Fargo, North Dakota (2.0 mi)
· Sponsor: Sameek Roychowdhury
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota (2.0 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities
Periprosthetic Joint Infections
N/A
Interventional 204 participants sought
Sanford South University Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: Elute, Inc.
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
Atopic Dermatitis (AD), Psoriasis (PsO)
Phase 1
Interventional 48 participants sought
Red River Research Partners — Fargo, North Dakota (2.0 mi)
· Sponsor: LAPIX Therapeutics Inc.
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,524 participants sought
Sanford Broadway Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 2
Interventional 240 participants sought
Sanford Broadway Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: NRG Oncology
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Phase 2
Interventional 396 participants sought
Sanford Broadway Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: SWOG Cancer Research Network
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Phase 1
Interventional 24 participants sought
Red River Research Partners — Fargo, North Dakota (2.0 mi)
· Sponsor: Incyte Corporation
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid Tumors, Hematologic Malignancies
Phase 3
Interventional 3,500 participants sought
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0065) — Fargo, North Dakota (2.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
Phase 3
Interventional 170 participants sought
Sanford Broadway Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
Sanford Health - Fargo — Fargo, North Dakota (2.0 mi)
· Sponsor: Novo Nordisk A/S
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
Phase 2
Interventional 70 participants sought
Sanford Broadway Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Melanoma, Lymphoma
Phase 1, Phase 2
Interventional 370 participants sought
Call for Information (Investigational Site 0070) — Fargo, North Dakota (2.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0056) — Fargo, North Dakota (2.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
Baseline ACL Injury Risk Screening and Normative Data
ACL Injury, Anterior Cruciate Ligament Injuries
N/A
Observational 5,000 participants sought
Sanford Health — Fargo, North Dakota (2.0 mi)
· Sponsor: Sanford Health
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Phase 2, Phase 3
Interventional 440 participants sought
Sanford Roger Maris Cancer Center — Fargo, North Dakota (2.0 mi)
· Sponsor: Exelixis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 1, Phase 2
Interventional 960 participants sought
Sanford Broadway Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: PedAL BCU, LLC
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Age-related Wet Macular Degeneration
Phase 1
Interventional 45 participants sought
CBCC Global Research Site:003 — Fargo, North Dakota (2.0 mi)
· Sponsor: Caregen Co. Ltd.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Cancer, Metastatic, Cancer
N/A
Observational 50,000 participants sought
Massive Bio SYNERGY-AI site — Fargo, North Dakota (2.0 mi)
· Sponsor: Massive Bio, Inc.
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Basal Ganglia Germinoma, Diabetes Insipidus
Phase 2
Interventional 240 participants sought
Sanford Broadway Medical Center — Fargo, North Dakota (2.0 mi)
· Sponsor: Children's Oncology Group
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NonSegmental Vitiligo
Phase 3
Interventional 180 participants sought
Red River Research Partners — Fargo, North Dakota (2.0 mi)
· Sponsor: Incyte Corporation
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Pyoderma Gangrenosum
Phase 3
Interventional 90 participants sought
Red River Research Partners, LLC — Fargo, North Dakota (2.0 mi)
· Sponsor: LEO Pharma